learn Redensyl
commercial product with a blend of mostly natural ingredients for hair regrowth
Search
forLearn
5 / 801 resultslearn TeraCeutic™
learn Fluridil
a topical anti-androgen with less systemic involvement
learn RU58841
a potent but unapproved and potentially problematic topical anti-androgen
learn Desonide
Research
5 / 1000+ resultsresearch Managing Skin Ageing as a Modifiable Disorder—The Clinical Application of Nourella® Dual Approach Comprising a Nano-Encapsulated Retinoid, Retilex-A® and a Skin Proteoglycan Replacement Therapy, Vercilex®
Nourella® effectively improves skin thickness and elasticity, reversing aging signs.
research Derma rollers in therapy: the transition from cosmetics to transdermal drug delivery
Derma rollers show promise for skin improvement and drug delivery, but more research is needed on their safety and effectiveness.
research Dermoscopy a Versatile Tool to Bust the Quackery
Dermoscopy helps diagnose skin issues and warns against unqualified treatments.
research A Multimodal Approach to Augmenting Wound Healing: Progress Toward Dermal Regeneration in Mammals
DPCs and new biomaterials can greatly improve skin healing.
research Re: Dermmatch, Inc.
Community Join
5 / 33 resultscommunity Veradermics is now public with a billion dollar market cap.
Veradermics has a market cap over a billion dollars, comparable to Cosmo pharmaceutical. Users discuss using Kintor's Pirylutamide for hair loss.
community How Veradermics secured a total of $220 million in series B and C financing for oral minoxidil, I will never understand.....
Veradermics' oral minoxidil shows promise for hair regrowth, with some users reporting significant improvements, while Pelage's PP405 results are less convincing and lack transparency. There is skepticism about both treatments' long-term effectiveness and potential side effects.
community People are hyped about PP405 but what about Veradermics phase 2!
Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.
community Veradermics VDPHL01: why isn’t anyone talking about it?
Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.
community If pp405 isnt the “cure” is there anything else that’s promising thats atleast better than min or dut?
Hair cloning and new treatments like ET-02, Veradermics (vdphl01), and wound-induced hair neogenesis show promise but are not yet widely available. Current effective treatments include minoxidil, finasteride, and dutasteride, with early intervention being crucial for better outcomes.